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Tumor necrosis factor a (TNFa) has multiple  biologi- 
cal  functions  including the prolonged activation of the 
collagenase and c;iun genes, which are regulated via 
their AP-1 binding sites. We show  that  incubating hu- 
man fibroblasts with TNFa induces prolonged activa- 
tion of JNK, the cJun kinase, which  phosphorylates the 
transactivation  domain of c-Jun. Furthermore,  an  im- 
mune complex kinase assay specifically demonstrates 
that TNFa stimulates  the activity of  JNK1, the recently 
described predominant form of JNK. TNFa also pro- 
duces a small and transient increase in extracellular 
signal-regulated kinase (ERK) activity and  no  measured 
increase in Raf-1 kinase activity. On the other  hand, epi- 
dermal  growth  factor causes a  prolonged  activation of 
Raf-1 kinase and ERK activity and  a  smaller,  more  tran- 
sient activation  of JNK, whereas the phorbol ester phor- 
bo1 12-myristate  13-acetate causes a  small  stimulation of 
Raf-1 kinase and  a  pronounced  stimulation of ERK ac- 
tivity. The activation of JNK by  TNFa does  not  correlate 
with  Raf-1  or ERK activity. The kinetics of Raf-1, ERK, 
and JNK induction by epidermal  growth  factor,  phorbol 
12-myristate  13-acetate,  or  TNFa indicate distinct 
mechanisms of activation in human  fibroblasts. 
Tumor  necrosis  factor a (TNFa),’ a potent  cytokine  produced 
mainly  by  activated  monocytes, has multiple biological func- 
tions  (1).  TNFa  actions are initiated  by  binding  to  two  distinct 
TNFa receptors of 55-60 kDa  (TNF  R-55  or  TNFR1) and 75-80 
kDa  (TNF  R-75 or TNFRB), which  have  different  affinities  for 
TNFa and may  mediate  different  downstream  responses (2-8). 
The  binding of TNFa  to  its  receptors  triggers the activation of 
several  second  messengers  through  stimulation of protein ki- 
nase C, sphingomyelinase, and phospholipase 4 (9-12). Expo- 
sure to TNFa also results in NFKB activation (13, 14) and 
stimulation of AP-1  activity (9). The final  nuclear targets for 
TNFa include genes containing AP-1 binding sites, such as 
collagenase and c-jun, and genes containing NFKB binding 
sites,  such as the  human  immunodeficiency  virus-long  terminal 
repeat and a variety of cytokine  genes  (9,  14, 15). 
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Incubating  cultured  fibroblasts  with  TNFa results in pro- 
longed  activation of the collagenase and c-jun genes as com- 
pared with incubating with the phorbol ester PMA (9). The 
stimulation of c-jun transcription  by  TNFa is independent of de 
nouo protein  synthesis (9). TNFa also  causes a transient acti- 
vation of the c-fos gene.  The  products of the c-fos and c-jun 
genes  are  components of the transcription  factor  AP-l(l6, 17). 
The  transcriptional  activity of the c-Jun  protein is regulated 
by its phosphorylation  status.  Phosphorylation of c-Jun at Thr- 
231,  Ser-243, and Ser-249  near  its  DNA  binding  domain  inhib- 
its  DNA  binding  and  therefore  reduces  transcriptional  activity 
(17, 18). Phosphorylation of two of these sites (Thr-231 and 
Ser-249) is catalyzed in. vivo and in  vitro  by  casein  kinase I1 
(18). Ser-243 is the major site of phosphorylation by E R G  
(19-21). On the other hand, phosphorylation of c-Jun in its 
activation  domain at Ser-63  and Ser-73 increases its transcrip- 
tional  activity (22-24) but  does  not  affect its DNA  binding  ac- 
tivity (25). Phosphorylation of the amino-terminal  activation 
domain is catalyzed by a specific Jun  nuclear kinase (JNK), 
which has been  recently  purified,  and  one of its  constituents, 
JNK1, has been  cloned (26, 27). 
In this  study, the pathways in human diploid  fibroblasts  by 
which  TNFa  stimulates  c-Jun are compared  with  those  stimu- 
lated  by  EGF  and the phorbol  ester PMA. PMA functions in 
par t  by  causing  dephosphorylation of residues  adjacent  to  the 
DNA binding domain in the carboxyl-terminal half of c-Jun 
(17). EGF  functions  through  multiple  signal  transduction  path- 
ways,  which  include the activation of Ras,  Raf, and extracellu- 
lar signal-regulated kinases (ERK1 and ERK2) (reviewed in  
Refs. 19 and 28). 
EXPERIMENTAL PROCEDURES 
Cell Culture-MRC-5 human fibroblast cells at the 14th passage 
were obtained from  ATCC  (CCL 171) and cultured in minimum essen- 
tial medium with Earle’s salts (Life  Technologies, Inc.) containing 10% 
fetal bovine serum (Gemini), 0.5 mg/ml L-glutamine,  180 unitdml pen- 
icillin G, and 180  pg/ml streptomycin (Irvine Scientific). 
Materials-Receptor grade EGF (Sigma) and TNFa (R & D Systems) 
were used at a final concentration of 10 ng/ml. PMA (Sigma) was used 
at a final concentration of 60 ng/ml. 
Plasmids-The luciferase reporter gene, ~XTRELUC, is described in 
Ref.  29 (gift of  K. Chien, University of California, San Diego).  pSVGal- 
Jun (amino acids 1-246 of cJun linked to the Gal4 DNA binding do- 
main), pSVGal-Jun(AA) (with serine 63 and serine 73 mutated to ala- 
nine), GST-Jun (amino acids 1-223 of c-Jun), and GST-JudAA) (with 
serine 63 and serine 73 mutated to alanine) are described in Ref. 26. 
Gal4-ElkC (Elk-1 codons 307-428) was  provided by R. Treisman (30). 
RSVc-Jun is described in Ref. 31. Ras N17 was a gift from C. Der. 
The kinase inactive MEK-1  expression construct was a gift from  G.  L. 
Johnson. 
Dansfections and Luciferase Assays-MRC-5 cells  were transfected 
by the calcium phosphate coprecipitation technique as previously de- 
scribed (32). Briefly, 5 pg of reporter gene  were cotransfected with 0.5 !-% 
of expression vector where indicated. Cells  were incubated in complete 
media  for 4 days after removing the precipitates, and  then the indicated 
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FIG. 1. TNFa, EGF, and PMA stimulate AP-1 transcriptional  activity. A, MRC-5 cells were  transfected  with  a  luciferase  reporter  gene 
containing two consensus  AP-1  binding  sites (2XTRE). Following transfection,  cultures were incubated  until  confluent (4 days)  and  then  stimulated 
for 5 h  with TNFcu, EGF, or PMA as  indicated. B,  MRC-5 cells were transfected  with 5XGal-Luc plus  the  Gal-Jun  expression vector or the  mutated 
version,  Gal-Jun(AA),  and  treated  as  in A. C, MRC-5 cells were  transfected  with the luciferase  reporter  gene  containing  5  Gal4  binding  sites 
(5XGal-Luc) and  the  expression vector Gal-ElkC. Cells were  treated  as  in  A.  The  graphs  represent  the  mean  values from two to four experiments 
performed in duplicate. Tx, treatment. 
factors  were  added.  5  h  after  factor  addition,  extracts for luciferase  and 
protein assays were prepared  as described (32). All luciferase values 
were normalized for extract  protein  concentration. 
Cellular Extmcts-Extracts were  prepared as  described in Ref. 33. 
The  nuclear  isolation  step  was  omitted for the  preparation of whole cell 
extracts. 
Cell Labeling, Immunoprecipitation, and Phosphopeptide Mapping- 
Subconfluent 100-mm plates of MRC-5 cells were labeled with 0.6 
mCi/ml "P (orthophosphate) or 150 pCi/ml Tran3?3-label (ICN). After 
2.5  h,  EGF or TNFcu was  added to the  media,  and cells were  incubated 
an additional 30 min before washing with phosphate-buffered saline 
and  lysis  in  radioimmune  precipitation buffer. Immunoprecipitation of 
endogenous c-Jun protein, transfer to nitrocellulose, and two-dimen- 
sional  phosphopeptide  mapping were performed as described  (32). No 
differences in  c-Jun  protein  content  between  treated  and  untreated cells 
were detected on ["Slmethionine-labeled gels (data not  shown).  Plates 
were exposed to film (Kodak X A R )  for 10  days a t  -85 "C. 
Gel Mobility Shifts Assays-Electrophoretic mobility shift assays 
were carried out as previously described (29) using 10 pg of MRC-5 
nuclear  extract  prepared a t  various  times following cell stimulation. An 
oligonucleotide representing  the  consensus  AP-1  binding  site from the 
human  collagenase  gene  (34)  was  synthesized on a Millipore Cyclone 
Plus  synthesizer  and  used  as probe. Polyclonal rabbit  anti-c-Jun  anti- 
serum  or  normal  rabbit  serum  was  added  where  indicated,  and  reac- 
tions  were  continued  another 20 min before loading  onto 4% non-dena- 
turing polyacrylamide gels. The anti-cJun  antisera  had no effect on 
binding  when  assayed  with  a  binding  site for HNF-1  (data  not  shown). 
In Vitro Kinase Assays-The solid-phase Jun  kinase assays were 
carried  out  as described (26)  using  a GST-c-Jun (1-223) fusion  protein 
coupled to glutathione-agarose beads as substrate. 50 pg of cellular 
extract  were  used  as  the  kinase  source.  The  mutated  version (GST-c- 
Jun  Ala 63,731 and GST protein  alone  were  used as control  substrates. 
Preparation of recombinant  kinase  inactive MEK-1, immunoprecipita- 
tion of Raf-1, and  Raf-1  immune complex kinase  assays  were performed 
as described (35). For  the  immune complex JNK1  assay,  50  pg of cellular 
extracts were immunoprecipitated with a specific antiserum raised 
against  recombinant  JNKl(271,  and  the  kinase  assay  was performed as 
described for Raf-1 with the addition of 20 p~ ATP, using GST-c-Jun as 
substrate.  Phosphorylated  proteins were resolved on 10% SDS-PAGE, 
radioactivity was visualized by autoradiography, and all gels were 
quantified by scintillation  counting of excised bands. 
In-&  ERK Assay-Activation of ERKl  and ERK2 was  determined 
using myelin basic  protein as  the  substrate  in  an in-gel kinase  assay  as 
described,  using  50  pg of each cell extract  (36).  The position of the ERKs 
was confirmed by comparison with both Rainbow molecular weight 
markers  (Amersham  Corp.)  and to low molecular weight protein  mark- 
ers (Life Technologies, Inc.). 
RESULTS 
TNFa Stimulates AP-1 Activity and c-dun Phospho- 
rylation-To assess  the effect of TNFa, PMA,  or EGF on AF-1 
transcriptional activity, MRC-5 fibroblasts were transfected 
with a luciferase reporter gene driven by AP-1 binding sites 
(BXTRE). As assessed by this assay, treatment with TNFa, 
EGF, or PMA stimulates  the endogenous AP-1 activity of the 
cells (Fig. lA), as previously demonstrated (9, 371, with PMA 
being the most  potent  activator. 
The  c-Jun  transactivation domain is  stimulated by its phos- 
phorylation at  Ser-63 and Ser-73 (as discussed below). To func- 
tionally assess  the effect of TNFa, EGF, or PMA  on the  trans- 
activation  domain, we transfected MRC-6 cells with an 
expression  construct encoding the activation domain of c-Jun 
fused to  the DNA binding domain of the Gal4 protein. This 
Gal4-Jun expression vector was  cotransfected  with a reporter 
gene containing five  copies of the Gal4 DNA binding domain 
linked to  the luciferase reporter gene (SXGal-Luc). Treatment 
with TNFa enhances the  c-Jun  transcriptional activity, result- 
ing  in  an increase of reporter gene activity ( p  < 0.05, Fig. 1B). 
Treatment with TNFa does not cause an increase in luciferase 
activity in  the presence of a mutated expression vector in which 
Ser-63  and  Ser-73  are changed to  alanines (Fig. 1B). EGF treat- 
ment  stimulates luciferase  activity to  a lesser  degree ( p  < 0.05), 
and PMA has no significant effect. Cotransfection with the 
dominant negative Ras N17 mutant does not inhibit TNFa 
stimulation of the  reporter gene (data not shown). 
Although ERK activation is critical in multiple signaling 
pathways, its role in  TNFa signaling is unknown. To function- 
ally assess ERK activation by TNFa, EGF, or  PMA, we trans- 
fected the fibroblasts  with an expression construct encoding the 
activation  domain of the  transcription factor Elk-1 fused to the 
DNA binding  domain of the Gal4 protein.  Phosphorylation of 
Elk-1 by ERKs stimulates the Elk-1 activation domain (30). 
This Gal-ElkC expression vector is cotransfected  with the 
5XGal-Luc reporter gene. Treatment  with PMA or to a lesser 
degree EGF enhances the  Elk-1  transcriptional activity (Fig. 
1C). TNFa weakly stimulates Elk-1 transcriptional activity, 
consistent with its minimal stimulation of ERK activity, as 
discussed below. 
To assess  the role of the  c-Jun protein in  stimulated AP-1 
activity, we investigated the effect of agonist treatment on its 
post-translational modification. Since TNFa induces c-jun 
transcription in the absence of de nwo protein synthesis (9), we 
assessed the effect of TNFa on c-Jun phosphorylation, the only 
known modification that affects c-Jun activity  (16). Treatment 
of fibroblasts  with either  TNFa or EGF for 30 min  increased 
I "Plphosphate  incorporation into  c-Jun  relative to untreated 
cells (Fig. U). Previous studies have demonstrated  that  the 
phosphorylated forms of c-Jun  are  present  in both bands seen 
in SDS-PAGE gels (38). Two-dimensional phosphopeptide maps 
demonstrated  that  treatment with TNFa increased phospho- 
rylation of Ser-63 and Ser-73 of c-Jun as indicated by the in- 
creased intensity of the X and Y phosphopeptides (Fig.  2B). 
Previous studies  demonstrated  thatXand Y contain  Ser-73 and 
Ser-63 (22, 23). No effect on the carboxyl-terminal sites was 
detected. In comparison, treatment with EGF (Fig. 2B) in- 
creased phosphorylation of the X phosphopeptide of c-Jun to a 
lesser  extent  than  TNFa  treatment  and induced no phospho- 
rylation of the Y peptide. On the  other  hand, EGF treatment 
increases the  intensity of the b and c carboxyl-terminal phos- 
26398 TNFa Stimulates  e-Jun Kinase Activity 
A 
Exlmt: c o n E  T P E T P E T P E T Pcomp 
4 
untreated TNFa EGF 
FIG. 2. TNFa and EGF modulate  phosphorylation of the cJun 
protein. A, cultures of MRC-5 cells were  labeled  with 0.6 mCi/ml "P 
(orthophosphate)  prior  to  stimulation  with  the  indicated  factors  for 30 
min.  Proteins  immunoprecipitated  with a cJun-specific  antisera  were 
subjected  to SDS-PAGE. The arrows indicate  the c J u n  protein. B, c-Jun 
protein from A was eluted, trypsinized, and subjected to two-dimen- 
sional phosphopeptide mapping. Spots representing specific peptides 
from the  amino-terminal  end of c J u n  (X, Y )  and  the  carboxyl-terminal 
end (a ,  6 ,  c )  are indicated. 
phopeptides  compared with  untreated  and  TNFa-treated cells. 
This  is  consistent  with activation of ERKs 1 and 2 by EGF (39). 
The  c-Jun phosphorylation pattern of PMA-treated  fibroblasts 
has been previously shown to consist of decreased phosphoryl- 
ation of sites  adjacent  to  the DNA binding  domain (17). 
PMA Zncreases AP-1 DNA Binding Activity-Next,  we per- 
formed gel mobility shift  assays with a radiolabeled AP-1 bind- 
ing  site probe incubated  with  nuclear  extracts  prepared from 
untreated  and  treated fibroblasts. Treatment with the phorbol 
ester PMA causes a rapid  and prolonged increased DNA bind- 
ing (Fig.  3A), which has previously been demonstrated  to  result 
from dephosphorylation of c-Jun  serine  residues  near  the DNA 
binding domain as well as increased Fos synthesis (17). In 
comparison, treatment with EGF  or  TNFa  results  in a smaller 
increase  in  the level of the AP-1 binding complexes (Fig. 3, A 
and B) .  To demonstrate that c-Jun contributes to the AP-1 
complex binding to  this probe, extracts from TNFa-treated cells 
a t  a variety of time points  were  used in mobility shift  assays  in 
the presence or absence of c-Jun-specific antiserum.  The dis- 
ruption of the AP-1 DNA complex by c-Jun  antiserum (Fig. 3C) 
demonstrates  that  c-Jun is a major constituent of the AP-1 
complex in control and  TNFa-treated cells. 
TNFa  Induces a Prolonged Activation of JNK-To determine 
whether TNFa-induced  phosphorylation of c-Jun  results from 
either increased JNK activity or decreased phosphatase activ- 
ity, we used a previously described solid-state  assay  to  measure 
JNK activity (26). Immobilized GST-c-Jun protein  (consisting 
of the activation  domain of c J u n  linked to GST) was  incubated 
with  fibroblast extracts  prepared at different time  points fol- 
lowing stimulation  with EGF, TNFa,  or PMA. TNFa  treatment 
results  in a biphasic  induction of c-Jun  kinase activity with an  
early maximal stimulation of greater  than 23-fold, followed  by 
a prolonged plateau stimulation persisting for at least 19 h 
(Fig. 4A and  data not  shown). On  the  other  hand,  treatment 
with PMA or  EGF  results  in a smaller, transient  stimulation of 
JNK activity with  rapid  return  to  basal levels (Fig. 4A). Quan- 
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FIG. 3. Effect of cytokine  treatment  on AP-1 DNA binding  ac- 
a radiolabeled human collagenase  probe in gel mobility shift  assays. 
Extracts from untreated  and  treated  MRCd cells were  incubated  with 
an excess of probe  on ice for 20 min, followed by non-denaturing gel 
electrophoresis.  Shifted complexes are indicated by the large arrow. T, 
TNFa; E, EGF; p ,  PMA, Fp, free probe; con, control cells; comp, com- 
petitor. B, quantitation of A expressed as  -fold increase over unstimu- 
lated levels. C, contribution of c-Jun to the AP-1 complex following 
TNFa  treatment.  Extracts,  prepared at the indicated  times  after  TNFa 
treatment, were incubated with an excess of probe with or without 
bit  serum (-) and subjected to electrophoresis as  in A. Specific shifted 
subsequent  incubation  with a c-Jun-specific antisera (+) or normal  rab- 
complexes, which were  disrupted by the  anti-c-Jun  antisera,  are shown. 
c-dun-Ab, c-Jun  antiserum. 
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FIG. 4. Activation  of JNK following  cytokine  treatment. A, recombinant  GST (lune 1 ), GST-cJun (lunes 3-21 1, or mutated  GSTJun(AA) 
(lune 2) were incubated  with 50 pg of extract from untreated cells (con) or cells treated for the indicated  time  period with TNFa (T), EGF ( E ) ,  or 
PMA (P). Phosphorylation  was  assessed by incorporation of [y-"*P]ATP in the c J u n  protein, followed by SDS-PAGE  and  autoradiography. The 
single bund represents  the GST-c-Jun  protein.  The  experiment  was  repeated  with three  separate  extract  preparations withp < 0.04 for TNFa versus 
control or EGF for all time points. B,  quantitation ofA expressed as -fold activation  over unstimulated levels. C, an immune  complex  kinase assay 
using JNK1-specific antiserum was performed with cell extracts from control cells or cells treated for the indicated  times with TNFa,  EGF, or PMA. 
titation of a representative  experiment is graphically depicted 
(as -fold increase over base-line  levels) in Fig. 4B. 
To directly assess  the effect of agonist  treatment on JNKl  
activity, an  immune complex kinase  assay  was performed using 
JNK1-specific antiserum. Although  all three  agonists  stimulate 
JNKl  activity compared with control cells, TNFa  treatment 
results  in  the  greatest  stimulation, followed  by EGF  and  then 
PMA (Fig. 4C).  After 10  min of incubation, JNKl  activity is 
stimulated 9.4-fold by TNFa, 5.8-fold by EGF, and 3.1-fold by 
PMA. 
TNFa Does Not Induce Raf-1 Kinase and  Dansiently Induces 
ERKs-Although recent studies have demonstrated a signal 
transduction  pathway  in which EGF receptor binding to its 
ligand  sequentially  activates Ras, Raf-1, and E R G  (19,28),  the 
signal  transduction  pathways for TNFa are largely  unknown. 
Therefore, we assessed Raf-1 kinase activity in MRC-5 fibro- 
blasts  after incubation with EGF, TNFa, or PMA. As expected, 
EGF  induces a large  and prolonged activation of Raf-1 kinase 
(Fig. 5 ,  A and B). PMA produces a lesser  stimulation while 
TNFa does not  stimulate Raf-1 kinase activity at any  measured 
time point. 
Finally, we examined whether ERKs are  activated  in  parallel 
with JNK. Using an  in-gel myelin basic  protein kinase  assay 
with  the  same  extracts  assayed for JNK  and Raf-1 kinase ac- 
tivity, a completely different temporal  pattern of stimulation is 
observed. TNFa-treated  extracts contain  elevated ERK activity 
only at  the  earliest  time points,  while PMA- or EGF-treated 
extracts  demonstrate  markedly elevated ERK activity at early 
time points followed by prolonged activity that remained 
greater  than 2-fold over base-line levels for 3 h (Fig. 6, A and 
B).  Improved resolution by a longer electrophoresis time  re- 
vealed the  appearance of two bands consistent with  the 
stimulation of ERKl  and ERK2 activity (data  not shown). The 
different effects of TNFa, PMA, and EGF on JNK  and ERK 
activity  were seen  in  several experiments using different ex- 
tract  preparations. 
DISCUSSION 
TNFa  actions  are  initiated by binding to two distinct mono- 
meric TNFa receptors, TNF R-55 and  TNF R-75, which are 
found in  nearly  all cells (5-8). Most of the downstream  signal- 
ing  events  initiated by TNFa receptor  binding has been attrib- 
uted  to  the  TNF R-55 (2,4,40). A knockout mouse in which the 
TNF R-55 gene is  disrupted  is  unable  to  mediate proper re- 
sponses to microorganisms, including endotoxic shock and 
clearance of Listeria monocytogenes (4, 40). The role of TNF 
R-75 is more controversial, but biological activities have been 
attributed  to  it, including cytotoxicity and cytokine secretion by 
T cells and  stimulation of TGFa mRNA levels (3, 41-43). Nei- 
ther  TNFa receptor has  intrinsic  kinase activity, and our un- 
derstanding of the  signal  transduction  pathways activated by 
TNFa  are incomplete. 
TNFa  increases  the levels of multiple second messengers. 
TNFa  has been demonstrated  to  activate phosphatidylcholine- 
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FIG. 5. TNFa treatment does not stimulate naf-1 mupase  acciv- 
ity.A, extracts from EGF- ( E ) ,  TNFa- (T), and PMA- (P) treated cells 
were  used as the  kinase  source  in a e-Raf-1 immune complex in vitro 
kinase assay. Kinase  inactive MEK-1 was  used  as  substrate.  Substrate 
alone (lane I )  and immunoprecipitated extract alone (lane 2 )  were 
included as controls.  The  prominent  band  migrating at 46  kDa  corre- 
sponds  to  the  size of recombinant MEK-1. con, control cells. B, quanti- 
tation of A expressed as -fold activation  over  unstimulated levels. 
specific phospholipase C, which in  turn produces diacylglycerol 
(2). Diacylglycerol is a classical second messenger  that  acti- 
vates protein kinase C, and, as expected,  protein kinase C is 
activated by TNFa (9). In addition, TNFa  activates sphingo- 
myelinase, which releases  the second messenger  ceramide (21, 
and some of the  TNFa biological activities  have been attributed 
to elevated ceramide levels (2, 44, 45). Furthermore, TNFa 
activates phospholipase 4, which produces the second messen- 
ger arachidonic acid with  the  subsequent  synthesis of leuko- 
trienes  and  prostaglandins  (2,lO). Finally, TNFa is reported to 
inhibit protein phosphatase activity (461, as many of the effects 
of TNFa  are mimicked by the  phosphatase inhibitor,  okadaic 
acid (47). 
TNFa induces the transcription factor NFKB (13, 14, 44), 
which requires  the  TNF R-55 as demonstrated by the inhibition 
of this  pathway  in  the  TNF R-55 knockout  mouse  (4). TNFa 
activates  NFKB by causing  the  rapid  degradation of IKB,  and 
the  released cytoplasmic NFKB  then  translocates  to  the  nu- 
cleus to  activate gene transcription (11). 
TNFa also stimulates the activity of transcription factor 
AF"1, which results  in increased  expression of the  cjun  and 
collagenase  genes (9)  and decreased  expression of the  elastin 
gene (48). The  present  study  demonstrates  that  TNFa  causes  
prolonged activation of JNK, a small  transient activation of 
ERK, and no increased  activation of Raf-1 kinase.  This  results 
in  the phosphorylation of the   cJun  activation domain with 
enhanced cdun  transcriptional activity and little change in 
cdun  DNA binding activity. 
This  study  demonstrates that  the  kinetics for the activation 
of JNK  and ERKs by TNFa, EGF, and PMA are different. Re- 
=t 
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FIG. 6. Activation of ERKs following cytokine  treatment. A, 50 
pg of the  indicated  extracts  were  electrophoresed on gels  containing 0.5 
mg/ml myelin  basic  protein. An in-gel kinase  assay  with [y-32PlATP was 
performed,  and  phosphorylated  myelin  basic  protein  was  visualized by 
autoradiography. Arrows represent p42 and p44 ERKs. Positions of 
ERKs  were confirmed with two different  size  standards  on  the gel (data 
not  shown).  Similar  results  were  obtained  in  three  independent experi- 
ments. B, quantitation of A (ERG)  expressed as  -fold activation over 
unstimulated levels. 
cent  studies  indicate  that  JNK1,  the 46-kDa protein that con- 
tributes  the  predominant  c-Jun amino-terminal kinase activity, 
is biochemically and immunologically distinct from ERKl  and 
ERK2 (26). Furthermore, JNK1, although a member of the 
mitogen-activated  protein kinase group, is  distantly  related  to 
ERKs 1 and 2 (27). Finally, overexpression and activation of 
ERKs 1 and 2 fail to  enhance  the  transcriptional activation of 
c-Jun by Ras or Raf (32). Altogether, these  results imply that 
JNK and ERKs are  distinct  proteins  and  are regulated by  dif- 
ferent, possibly parallel,  signal  transduction pathways. There- 
fore, the activities of JNK and ERKs can be independently 
regulated. 
The  signal  transduction  pathway by which TNFa activates 
JNK is unknown.  Since oncogenic Ras proteins  activate JNK 
and  enhance  c-Jun  transactivation activity (22,32),  the role of 
Ras  and Raf in  TNFa signal transduction needs to be assessed. 
A dominant negative mutant  Ras (H-Ras  N17) has been used to 
demonstrate  the  requirement for endogenous activation in sig- 
nal pathways, including insulin  and platelet-derived growth 
factor  activation of ERK2 (49) and UV induction of NFKB (50). 
However, H-Ras N17 alone failed to  inhibit EGF  stimulation of 
ERK2 in  murine fibroblast cell lines, which required  simulta- 
neous  inhibition of additional  pathways (51). Since H-Ras N17 
fails  to  inhibit  TNFa  stimulation of c-Jun transcriptional ac- 
tivity, this implies a Ras-independent pathway for TNFa 
signaling. 
Activated Ras  stimulates ERKs in a variety of cell types (49, 
52-54). Ras directly interacts  with  the amino-terminal  regula- 
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tory domain of Raf-1, which in  turn  leads  to phosphorylation 
and  activation of MEK-1 and MEK-2 in a variety of cells, in- 
cluding  fibroblasts (55-58). Recent work demonstrates  that Raf 
activity is a necessary component for activation of ERK by 
oncogenes, serum,  and PMA (59). Our  study confirms the acti- 
vation of Raf and ERKs by PMA and EGF. However, TNFa does 
not  stimulate Raf-1 kinase activity and only transiently  stimu- 
lates ERK activity, presumably through a Raf-independent 
pathway  such as MEKK (60). Thus,  this  study provides evi- 
dence that TNFa activates  JNK  through a  Ras-, Raf-, and ERK- 
independent pathway. 
Addendum-While this paper was under review, Kyriakis et al. (61) 
reported a family of cJun kinases  that includes JNKl and is activated 
by TNFa. 
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